• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    November 14, 2023 - FDA Roundup: November 14, 2023

    11/14/23 3:26:18 PM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary
    Get the next $AMZN alert in real time by email
    For Immediate Release:
    November 14, 2023

    Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: 

    • On Monday, the FDA updated the advisory for the Investigation of Elevated Lead Levels in Cinnamon Applesauce Pouches to include an expanded recall from WanaBana LLC to include Weis and Schnucks-brand cinnamon applesauce pouches. As of November 13, 2023, there have been 22 reports of illness potentially linked to recalled product submitted to the FDA. The FDA is continuing to evaluate incoming adverse reports of illnesses. The FDA’s investigation is ongoing to determine the source of lead contamination and whether additional products are linked to illnesses. The FDA will update this advisory as information becomes available.
    • On Monday, the FDA issued a warning letter to Amazon.com, Inc. for the firm’s distribution of “Similasan Pink Eye Relief,” “The Goodbye Company Pink Eye,” “Can-C Eye Drops,” “Optique 1 Eye Drops,” “OcluMed Eye Drops,” “TRP Natural Eyes Floaters Relief” and “Manzanilla Sophia Chamomile Herbal Eye Drops” products. These products are not generally recognized as safe and effective for their claimed uses, including temporary relief of minor eye symptoms such as excessive watery (clear) discharge, sensation of grittiness, redness and burning, or pink eye. Therefore, these products are categorized as “new drugs” under the Federal Food, Drug & Cosmetic Act. Ophthalmic drug products are especially concerning from a public health perspective. Products intended for use in the eyes generally pose a greater risk of harm to users because the route of administration for these products bypasses some of the body’s natural defenses. 

    The FDA encourages consumers and health care professionals to report any adverse reactions to the agency’s MedWatch program.

    • On Thursday, the FDA published a safety advisory about an investigation, in collaboration with the U.S. Centers for Disease Control (CDC) and state partners, into human cases of Salmonella Kiambu infection that are potentially associated with pet food made by Mid America Pet Food. Epidemiological data and advice from the CDC can be found in the CDC pet food safety alert.

    Mid America Pet Food has voluntarily recalled all the pet food brands it manufactured with a best by date before 10/31/2024. This includes Victor, Eagle Mountain, Wayne Feeds and two varieties of Member’s Mark pet foods. These products include both dog and cat foods and were sold nationwide in retail stores and online. A full list of the recalled products can be found in the advisory. The investigation is ongoing, and the FDA will update this advisory as appropriate. 

    • On Thursday, the FDA issued a Letter to Health Care Providers about labeling updates for Becton, Dickinson and Company (BD) surgical mesh products. The FDA is aware of increased use of surgical mesh products in breast surgery. The safety and effectiveness of surgical mesh in breast surgery, including in augmentation or reconstruction, has not been determined by the FDA. There are no surgical mesh products cleared or approved by FDA for use in breast surgery, including in augmentation or reconstruction.
    • On Wednesday, the FDA approved fruquintinib (Fruzaqla, Takeda Pharmaceuticals, Inc.) for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy. View full prescribing information for fruquintinib. 
    • On Wednesday, the FDA authorized for marketing the Owlet Baby Care, Inc.’s Dream Sock, an over-the-counter device to monitor the pulse rate and oxygen saturation measurements for infants one to 18 months of age and between six to 30 pounds. This device is intended for use in a home environment and not intended for use with infants previously diagnosed with cardiovascular or respiratory conditions. The safety and effectiveness of this device for the detection or prevention of SIDS/SUID has not been established.
    • On Tuesday, November 7, the FDA revised the existing indication of pembrolizumab (Keytruda, Merck) with trastuzumab, fluoropyrimidine, and platinum-containing chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma. This updated indication, which remains approved under accelerated approval regulations, restricts its use to patients whose tumors express PD-L1 (CPS ≥ 1) as determined by an FDA-approved test. The FDA also approved the Agilent PD-L1 IHC 22C3 pharmDx as a companion diagnostic device to select patients with gastric or GEJ adenocarcinoma whose tumors express PD-L1 (CPS ≥ 1). View full prescribing information for Keytruda.
    • On Tuesday, November 7, the FDA issued a warning letter to Nic Nac Naturals, LLC for the marketing of their unauthorized dissolvable nicotine products, which the company describes as “nicotine mints” and resemble a pack of mints. The manufacturer markets these tobacco products in a variety of mint and fruit flavors, all of which come in two nicotine strengths (3 milligrams or 6 milligrams). These products are of particular concern because of their resemblance to popular candies and the potential to cause severe nicotine toxicity or even death if accidentally ingested by young children. 
    • On Tuesday. November 7, the FDA approved the ReCor Medical’s Paradise Ultrasound Renal Denervation System, the first breakthrough designated device intended to treat patients with hypertension in whom lifestyle modifications and antihypertensive medications do not adequately control blood pressure. The system delivers through a catheter ultrasound energy that heats and disrupts nerves surrounding kidney blood vessels. Reduced activity of these nerves results in blood pressure reduction. Hypertension affects approximately 45% of US adults and is linked to an increased risk of stroke, heart disease, and renal disease. Three clinical trials of the ReCor device showed that treatment with the Paradise System led to reduced blood pressure through 2 months after the procedure.

    Related Information

    Related Information
    • FDA Newsroom

    ###

    Boilerplate

    The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.


    Inquiries

    Media:
    FDA Office of Media Affairs
    888-INFO-FDA
    Consumer:
    888-INFO-FDA

     
    Get the next $AMZN alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $AMZN

    DatePrice TargetRatingAnalyst
    7/23/2025$248.00 → $265.00Buy
    BofA Securities
    7/22/2025$220.00 → $265.00Buy
    Needham
    7/21/2025$220.00 → $244.00Outperform
    Robert W. Baird
    7/11/2025$240.00 → $255.00Overweight
    Analyst
    7/10/2025Mkt Outperform
    Citizens JMP
    7/8/2025$201.00 → $238.00Equal Weight
    Wells Fargo
    7/2/2025$226.00 → $250.00Buy
    Truist
    6/27/2025$254.00Neutral → Outperform
    BNP Paribas Exane
    More analyst ratings

    $AMZN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Roundhill Investments Launches Five Additional WeeklyPay™ ETFs

      Roundhill WeeklyPay™ ETFs are designed to deliver weekly distributions while targeting enhanced weekly returns linked to investors' favorite stocks. NEW YORK, July 24, 2025 /PRNewswire/ -- Roundhill Investments, an ETF sponsor focused on innovative financial products, is pleased to announce the launch of five new WeeklyPay™ ETFs, which begin trading on Cboe BZX today. Today's launch expands the Roundhill WeeklyPay™ ETF suite to fifteen funds, encompassing fifteen underlying stocks: AAPL, AMD, AMZN, AVGO, BRK/B, COIN, GOOGL, HOOD, META, MSFT, MSTR, NFLX, NVDA, PLTR, and TSLA. T

      7/24/25 9:00:00 AM ET
      $AAPL
      $AMD
      $AMZN
      $AVGO
      Computer Manufacturing
      Technology
      Semiconductors
      Catalog/Specialty Distribution
    • Roundhill WeeklyPay™ ETF Suite Surpasses $250 Million in AUM

      WeeklyPay™ ETFs are designed to deliver weekly income and uncapped upside on your favorite stocks. NEW YORK, July 23, 2025 /PRNewswire/ -- Roundhill Investments, an ETF sponsor focused on innovative financial products, is excited to announce that its WeeklyPay™ ETF suite has exceeded $250 million in assets under management (AUM).¹ Roundhill WeeklyPay™ ETFs are designed to provide investors with weekly distributions while allowing investors to maintain uncapped upside exposure to their favorite stocks, unlike covered call funds. About Roundhill Investments: Founded in 2018, Roundhill Investments is an SEC-registered investment advisor focused on innovative exchange-traded funds. Roundhill's

      7/23/25 4:36:00 PM ET
      $AMZN
      $NVDA
      Catalog/Specialty Distribution
      Consumer Discretionary
      Semiconductors
      Technology
    • Buy with Prime Powers Revlon's Limited-Edition "Flavortown" Lip Balm Launch with Guy Fieri

      Customers can order Revlon's limited-edition Super Lustrous Glass Shine Lip Balm with the power of Amazon's fulfillment network and the trust of Prime Through fast, free delivery, easy returns, and 24/7 support, Buy with Prime enhances the purchasing experience for Revlon's limited lip balm drop Prime members get the familiar shopping benefits they know and love on Revlon.com Amazon (NASDAQ:AMZN) today announced that Revlon's limited-edition "Flavortown" shade of its Super Lustrous Glass Shine Lip Balm—created in collaboration with Guy Fieri—is exclusively available through Buy with Prime, a direct-to-customer (DTC) offering, now through July 29. Timed to celebrate National Lipstick D

      7/23/25 9:00:00 AM ET
      $AMZN
      Catalog/Specialty Distribution
      Consumer Discretionary

    $AMZN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • March 11, 2025 - FDA Roundup: March 11, 2025

      For Immediate Release: March 11, 2025 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:Today, the FDA published a General Correspondence Letter issued to Mid-Link Technology Testing Co., Ltd. The FDA is vigilant in ensuring data submitted to the FDA can be relied upon to assess the effectiveness, safety, or risk of a device. The FDA has noted an incr

      3/13/25 3:14:00 PM ET
      $AMZN
      Catalog/Specialty Distribution
      Consumer Discretionary
    • November 14, 2023 - FDA Roundup: November 14, 2023

      For Immediate Release: November 14, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Monday, the FDA updated the advisory for the Investigation of Elevated Lead Levels in Cinnamon Applesauce Pouches to include an expanded recall from WanaBana LLC to include Weis and Schnucks-brand cinnamon applesauce pouches. As of November 13, 2023, there

      11/14/23 3:26:18 PM ET
      $AMZN
      Catalog/Specialty Distribution
      Consumer Discretionary

    $AMZN
    SEC Filings

    See more
    • SEC Form SD filed by Amazon.com Inc.

      SD - AMAZON COM INC (0001018724) (Filer)

      5/30/25 4:06:48 PM ET
      $AMZN
      Catalog/Specialty Distribution
      Consumer Discretionary
    • Amazon.com Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - AMAZON COM INC (0001018724) (Filer)

      5/22/25 4:31:45 PM ET
      $AMZN
      Catalog/Specialty Distribution
      Consumer Discretionary
    • SEC Form 144 filed by Amazon.com Inc.

      144 - AMAZON COM INC (0001018724) (Subject)

      5/15/25 4:29:41 PM ET
      $AMZN
      Catalog/Specialty Distribution
      Consumer Discretionary

    $AMZN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BofA Securities reiterated coverage on Amazon with a new price target

      BofA Securities reiterated coverage of Amazon with a rating of Buy and set a new price target of $265.00 from $248.00 previously

      7/23/25 11:29:18 AM ET
      $AMZN
      Catalog/Specialty Distribution
      Consumer Discretionary
    • Needham reiterated coverage on Amazon with a new price target

      Needham reiterated coverage of Amazon with a rating of Buy and set a new price target of $265.00 from $220.00 previously

      7/22/25 8:59:18 AM ET
      $AMZN
      Catalog/Specialty Distribution
      Consumer Discretionary
    • Robert W. Baird reiterated coverage on Amazon with a new price target

      Robert W. Baird reiterated coverage of Amazon with a rating of Outperform and set a new price target of $244.00 from $220.00 previously

      7/21/25 9:25:07 AM ET
      $AMZN
      Catalog/Specialty Distribution
      Consumer Discretionary

    $AMZN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Executive Chair Bezos Jeffrey P sold $1,509,959,637 worth of shares (6,612,707 units at $228.34), decreasing direct ownership by 0.74% to 887,933,999 units (SEC Form 4)

      4 - AMAZON COM INC (0001018724) (Issuer)

      7/23/25 4:30:09 PM ET
      $AMZN
      Catalog/Specialty Distribution
      Consumer Discretionary
    • Executive Chair Bezos Jeffrey P sold $166,449,709 worth of shares (733,195 units at $227.02), decreasing direct ownership by 0.08% to 894,546,706 units (SEC Form 4)

      4 - AMAZON COM INC (0001018724) (Issuer)

      7/17/25 4:48:35 PM ET
      $AMZN
      Catalog/Specialty Distribution
      Consumer Discretionary
    • Executive Chair Bezos Jeffrey P sold $1,512,356,060 worth of shares (6,715,424 units at $225.21), decreasing direct ownership by 0.74% to 895,279,901 units (SEC Form 4)

      4 - AMAZON COM INC (0001018724) (Issuer)

      7/15/25 4:22:10 PM ET
      $AMZN
      Catalog/Specialty Distribution
      Consumer Discretionary

    $AMZN
    Financials

    Live finance-specific insights

    See more
    • Amazon.com to Webcast Second Quarter 2025 Financial Results Conference Call

      Amazon.com, Inc. (NASDAQ:AMZN) announced today that it will hold a conference call to discuss its second quarter 2025 financial results on Thursday, July 31, 2025, at 2:00 p.m. PT/5:00 p.m. ET. The event will be webcast live, and the audio and associated slides will be available for at least three months thereafter at www.amazon.com/ir. View source version on businesswire.com: https://www.businesswire.com/news/home/20250717192665/en/ Amazon.com Public Relations [email protected] amazon.com/ir

      7/17/25 4:01:00 PM ET
      $AMZN
      Catalog/Specialty Distribution
      Consumer Discretionary
    • Amazon.com Announces First Quarter Results

      Amazon.com, Inc. (NASDAQ:AMZN) today announced financial results for its first quarter ended March 31, 2025. Net sales increased 9% to $155.7 billion in the first quarter, compared with $143.3 billion in first quarter 2024. Excluding the $1.4 billion unfavorable impact from year-over-year changes in foreign exchange rates throughout the quarter, net sales increased 10% compared with first quarter 2024. North America segment sales increased 8% year-over-year to $92.9 billion. International segment sales increased 5% year-over-year to $33.5 billion, or increased 8% excluding changes in foreign exchange rates. AWS segment sales increased 17% year-over-year to $29.3 billion. Operati

      5/1/25 4:01:00 PM ET
      $AMZN
      Catalog/Specialty Distribution
      Consumer Discretionary
    • Amazon.com to Webcast First Quarter 2025 Financial Results Conference Call

      Amazon.com, Inc. (NASDAQ:AMZN) announced today that it will hold a conference call to discuss its first quarter 2025 financial results on Thursday, May 1, 2025, at 2:00 p.m. PT/5:00 p.m. ET. The event will be webcast live, and the audio and associated slides will be available for at least three months thereafter at www.amazon.com/ir. View source version on businesswire.com: https://www.businesswire.com/news/home/20250417424996/en/ Amazon.com Public Relations [email protected] amazon.com/ir

      4/17/25 4:01:00 PM ET
      $AMZN
      Catalog/Specialty Distribution
      Consumer Discretionary

    $AMZN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Amazon.com Inc.

      SC 13G/A - AMAZON COM INC (0001018724) (Subject)

      11/8/24 4:33:15 PM ET
      $AMZN
      Catalog/Specialty Distribution
      Consumer Discretionary
    • Amendment: SEC Form SC 13G/A filed by Amazon.com Inc.

      SC 13G/A - AMAZON COM INC (0001018724) (Filed by)

      11/7/24 5:23:12 PM ET
      $AMZN
      Catalog/Specialty Distribution
      Consumer Discretionary
    • SEC Form SC 13G/A filed by Amazon.com Inc. (Amendment)

      SC 13G/A - AMAZON COM INC (0001018724) (Subject)

      2/13/24 4:55:57 PM ET
      $AMZN
      Catalog/Specialty Distribution
      Consumer Discretionary

    $AMZN
    Leadership Updates

    Live Leadership Updates

    See more
    • eero Celebrates a Decade of Innovation with All-New Wi-Fi 7 Products

      After launching the powerful eero Max 7 and the tough eero Outdoor 7, eero expands Wi-Fi 7 portfolio with all-new eero 7 and eero Pro 7 eero 7 is the company's most affordable Wi-Fi 7 router, offering multi-gigabit speeds in a compact form factor eero Pro 7 delivers premium Wi-Fi 7 performance for high-bandwidth connectivity needs, offering fast wireless and wired speeds with two 5 GbE ports, and capacity for hundreds of devices Amazon (NASDAQ:AMZN) announced that eero is expanding its Wi-Fi 7 portfolio to include eero 7, delivering multi-gigabit speeds at a more affordable price, and eero Pro 7, offering premium performance for bandwidth-demanding networks. Thanks to the company's TrueM

      2/19/25 11:09:00 AM ET
      $AMZN
      Catalog/Specialty Distribution
      Consumer Discretionary
    • IMDb Announces Leadership Transition as Company Marks 35th Anniversary

      Founder Col Needham Becomes Executive Chair, Nikki Santoro Named CEO, Positioning IMDb for Next Phase of Innovation and Growth IMDb (www.imdb.com), the world's most popular and authoritative source for information on movies, TV shows, and celebrities, today announced that Founder & Chief Executive Officer Col Needham has transitioned to the role of Founder & Executive Chair. Nikki Santoro, who has served as IMDb Chief Operating Officer since 2021, has been appointed the Chief Executive Officer of IMDb. This marks a significant milestone in the company's 35-year history, with Santoro becoming only the second CEO and the first woman to hold the role. This press release features multimedia.

      1/21/25 10:00:00 AM ET
      $AMZN
      Catalog/Specialty Distribution
      Consumer Discretionary
    • Superapp Grab Selects AWS as its Preferred Cloud Provider to Drive Technology Innovation and Growth

      Southeast Asia's leading superapp leverages AWS to enhance operational efficiency across eight countries At AWS re:Invent, Amazon Web Services, Inc. (AWS), an Amazon.com, Inc. company (NASDAQ:AMZN), and Grab, Southeast Asia's leading superapp (NASDAQ:GRAB), announced that Grab has selected AWS as its preferred cloud provider. With AWS, Grab is pursuing a technology-led strategy to accelerate growth across its mobility, deliveries, and financial services verticals, including its new digibanks, while continuing to improve its operational efficiencies and reduce IT infrastructure costs. Grab relies on the world's leading cloud to serve 41.9 million monthly transacting users1 and over 13 mi

      12/4/24 6:30:00 PM ET
      $AMZN
      $GRAB
      Catalog/Specialty Distribution
      Consumer Discretionary
      Business Services